Skip to main content
رجوع
GZPHF logo

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

جودة البيانات: 100%
ذروة شراء
GZPHF
OTC Healthcare Drug Manufacturers - Specialty & Generic
KWD 2.34
▼ KWD 0.20 (-8.55%)
القيمة السوقية: 5.93B
نطاق اليوم
KWD 2.34 KWD 2.34
نطاق 52 أسبوعًا
KWD 2.14 KWD 2.88
حجم التداول
300
متوسط 50 يوم / 200 يوم
KWD 2.26 / KWD 2.31
الإغلاق السابق
KWD 2.34

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E 2.0 0.4
P/B 0.2 2.9
ROE % 7.9 3.7
Net Margin % 3.9 3.8
Rev Growth 5Y % 2.3 10.0
D/E 0.6 0.2

النقاط الرئيسية

Revenue grew 2.25% annually over 5 years — modest growth
Negative free cash flow of -954.41M
P/E of 2.04 — trading at a low valuation
Capital efficient — spends only 1.60% of revenue on capex
ROIC of 3.87% — low return on invested capital

النمو

Revenue Growth (5Y)
2.25%
Revenue (1Y)0.61%
Earnings (1Y)2.49%
FCF Growth (3Y)N/A

الجودة

Return on Equity
7.89%
ROIC3.87%
Net Margin3.85%
Op. Margin4.01%

الأمان

Debt / Equity
0.55
Current Ratio1.57
Interest Coverage7.26

التقييم

P/E Ratio
2.04
P/B Ratio0.16
EV/EBITDA3.87
Dividend Yield0.05%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 0.61% Revenue Growth (3Y) -0.05%
Earnings Growth (1Y) 2.49% Earnings Growth (3Y) -15.35%
Revenue Growth (5Y) 2.25% Earnings Growth (5Y) -5.99%
Profitability
Revenue (TTM) 75.45B Net Income (TTM) 2.91B
ROE 7.89% ROA 3.44%
Gross Margin 15.18% Operating Margin 4.01%
Net Margin 3.85% Free Cash Flow (TTM) -954.41M
ROIC 3.87% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.55 Current Ratio 1.57
Interest Coverage 7.26 Dividend Yield 0.05%
Valuation
P/E Ratio 2.04 P/B Ratio 0.16
P/S Ratio 0.08 PEG Ratio 1.82
EV/EBITDA 3.87 Dividend Yield 0.05%
Market Cap 5.93B Enterprise Value 11.69B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 75.45B 74.99B 75.52B 70.79B 69.01B
Net Income 2.91B 2.84B 4.06B 3.97B 3.72B
EPS (Diluted) 1.82 1.74 2.49 2.44 2.29
Gross Profit 11.46B 12.52B 14.19B 13.28B 13.23B
Operating Income 3.02B 3.60B 5.12B 5.07B 4.79B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 84.55B 81.68B 78.59B 74.67B 66.12B
Total Liabilities 43.41B 43.91B 41.91B 41.03B 34.79B
Shareholders' Equity 37.81B 35.90B 34.92B 32.07B 29.06B
Total Debt 20.70B 12.37B 11.70B 11.43B 9.92B
Cash & Equivalents 14.95B 18.27B 21.31B 22.50B 22.38B
Current Assets 61.55B 57.76B 55.98B 57.06B 52.81B
Current Liabilities 39.14B 38.92B 36.24B 37.40B 32.25B